Adlai Nortye
Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy.
Market cap
$57.2m
Enterprise value
$24m
Share price
$1.47 ANL
loading funding rounds…
Detong Capital(exited)
Matrix Partners China(exited)
YuanMing Capital(exited)
CMG-SDIC Capital(exited)
Tigermed(exited)
Legend Star(exited)
WuXi Biologics(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (119 %) | - | (2024 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (124 %) | - | (2097 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 92 % | - | 1163 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.